The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).
D. Nosov
No relevant relationships to disclose
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
W. B. Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
A. L. Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
O. N. Lipatov
No relevant relationships to disclose
O. O. Lyulko
No relevant relationships to disclose
A. O. Anischenko
No relevant relationships to disclose
R. T. Chacko
No relevant relationships to disclose
D. Doval
No relevant relationships to disclose
W. J. Slichenmyer
Employment or Leadership Position - AVEO
Stock Ownership - AVEO